Myths Missouri families believe about what moves a loved one

When someone you love is stuck in depression or PTSD that treatment has not touched, you start forming theories about what will finally get through. If I find the right article. If I say it the right way. If they just saw the right video. Families across Missouri carry these theories around for years, and some of them quietly work against the goal.

A survey our publisher commissioned in June offers a reality check. It put to 443 adults from ten Midwest states, Missouri among them, a set of questions about how they would choose a newer depression treatment. It was a general-public sample, not a survey of families or of people with PTSD, and the figures below apply to the whole group. They are the final, validated figures.

Myth 1: If I push hard enough, they will go

The data points elsewhere. On the question of who could get them to actually try ketamine or esketamine, the physician people already see was the runaway answer at 74 percent. Relatives and friends were a distant second, 18 percent.

Eighteen percent is not nothing. It beats every media source we tested combined. But it suggests family influence works best as encouragement toward a doctor, not as a campaign of its own. Pushing a specific treatment can make the conversation about you rather than about them.

Myth 2: Once they see enough about it online, they will come around

Media barely moved anyone. In the same question, ads persuaded 2 percent. Podcast hosts persuaded 1 percent. A veteran or first responder people follow online persuaded 4 percent.

There is a practical reason, too. When the survey asked what people would actually type into a search bar if they needed help, 319 people answered, and they wrote in the language of feelings and pleas: "depressed," "ptsd treatments," "how to overcome depression," "someone please help me." Nobody typed a drug name. Your loved one is unlikely to stumble on a specific treatment unless someone they trust names it for them.

Myth 3: They probably already know about the newer options

Most people do not. The name Spravato was brand new to 73 percent of respondents. About one in five, 21 percent, recognized the word but not the treatment behind it. A slim 6 percent could actually describe it.

If you have been reading about esketamine for months, you may be far ahead of the person you are worried about. That is a reason for patience. Something new and unfamiliar lands better when a clinician explains it in context than when it arrives as a printout on the kitchen table.

Myth 4: Esketamine is a PTSD treatment

Not by its FDA approval. Esketamine, marketed under the name Spravato, has an FDA approval covering adults whose depression is treatment-resistant and, paired with an oral antidepressant, for adults in a major depressive episode marked by suicidal thinking or actions. It is not approved for PTSD. Research on ketamine and PTSD exists, but studied is not the same as approved.

Many people live with depression and PTSD together, and a clinician can help untangle which is driving what. PTSD has its own well-established treatments, including trauma-focused psychotherapies. If PTSD is the main struggle in your family, those deserve a direct question at the appointment.

Setting matters here as well. Spravato is given only in certified clinics, with observation after each dose. At-home ketamine that telehealth companies sell is off-label and far less supervised. They are different things. Brain Recovery Centers describes how supervised Spravato sessions work.

Myth 5: If the doctor says no, the door is closed

A no is information, not the end. A doctor may decline a newer treatment for good reasons: blood pressure, substance use history, other medications, or because first-line options have not been fully tried. A thoughtful no comes with a reason and an alternative. If the explanation is missing, asking for a psychiatry referral or a second opinion is reasonable.

Many people start with a generalist anyway. The survey's first-stop question sent 56 percent to their primary doctor and 23 percent to psychiatry or another branch of mental health care. Moving from one to the other is a normal part of the process, not a sign it failed.

Myth 6: People are mostly against this kind of treatment

Doubt, yes. Hostility, rarely. Offered a gut-check question in our survey about ketamine therapy for depression or PTSD, a combined 51 percent tilted toward openness, counting the 34 percent who were cautious yet willing and the 18 percent who were hopeful or curious. Missouri's own 55 respondents leaned open at 55 percent. Skeptics made up 21 percent. Just 9 percent were negative, while 18 percent were meeting the idea for the first time.

Your loved one, if they hesitate, is probably in the cautious middle. People there tend to respond to trustworthy signals. FDA approval weighed heavily or decisively for 59 percent, and coverage landed on the top-two list for 85 percent.

What families can do instead

• Talk about how they seem, not about a particular drug.
• Offer help drafting a medication history: what was tried, for how long, what happened.
• Offer to book the appointment or drive them there.
• Ask whether you should sit in on the visit, and honor what they say.
• If you are on the same insurance, call and ask what is covered and whether prior authorization applies.
• MO HealthNet members can ask their Missouri managed care plan to name in-network psychiatrists who are taking new patients.

You are also in large company. In the survey, 72 percent told us standard medication had fallen short on depression, anxiety, or PTSD for themselves, for someone close, or for both.

Please take this as orientation for families rather than medical advice. Some people are helped by a given treatment and some are not, and suitability is always a clinician's call.

If you believe a loved one might be thinking of ending their life, trust that instinct and act. Relatives can use 988 too: call or text, and a Lifeline counselor will help you think through what to do. If anyone is in immediate danger, call 911 and stay close.

Methodology

Our publisher initiated and funded this survey. Pollfish administered it via its consumer panel, with fielding closed on June 23, 2026 and n=443 adult respondents aged 18 to 64 in Missouri, Oklahoma, Iowa, Kansas, Illinois, Nebraska, Indiana, Minnesota, Ohio, and Wisconsin. Only the Missouri number is a subgroup; everything else describes all 443, and all are final after the panel's validation.